Related Experiment Video

Updated: May 27, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Treatment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race

J de Castro-Carpeño1, R Perona, C Belda-Iniesta

  • 1Instituto de Investigación Hospital Universitario La Paz (IdiPAZ), Servicio de Oncología Médica, Hospital Universitario La Paz, Madrid, Spain. jcastro.hulp@salud.madrid.org

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|November 16, 2011
PubMed

Insights

Anaplastic lymphoma kinase (ALK) rearrangements are key in nonsmall-cell lung cancer (NSCLC) treatment. This review covers diagnosing ALK-rearranged NSCLC and crizotinib

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Anaplastic lymphoma kinase (ALK) rearrangements are identified in a subset of nonsmall-cell lung cancer (NSCLC) patients.
  • Targeted therapies, like crizotinib, offer new treatment avenues for ALK-positive NSCLC.

Purpose of the Study:

  • To review clinical aspects of ALK alterations in NSCLC.
  • To address diagnostic methods for ALK-rearranged NSCLC.
  • To evaluate crizotinib's efficacy, toxicity, and resistance mechanisms.

Main Methods:

  • Literature review of clinical studies on ALK rearrangements in NSCLC.
  • Analysis of diagnostic techniques for ALK alterations.
  • Review of clinical trial data for crizotinib in NSCLC.

Main Results:

  • ALK rearrangements represent a significant therapeutic target in NSCLC.
  • Effective diagnosis of ALK-rearranged NSCLC is crucial for treatment selection.
  • Crizotinib demonstrates efficacy but also presents challenges regarding toxicity and resistance.

Conclusions:

  • ALK alterations are a critical factor in NSCLC patient management.
  • Optimal diagnostic strategies are needed to identify patients benefiting from ALK inhibitors.
  • Understanding and overcoming resistance mechanisms to crizotinib is essential for improving patient outcomes.

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...